Cell therapy clinical trials for solid tumors, BMT attending
Houston, TX
Joined September 2010
- Tweets39
- Following121
- Followers122
- Likes115
David Steffin retweeted
A 3-year-old boy with chemotherapy-resistant metastatic hepatoblastoma had complete regression lasting at least 12 months after two infusions of glypican-3–specific CAR T cells coexpressing interleukin-15 and interleukin-21. Read the full correspondence: nej.md/46a2Iut
ALT The image is a graph showing alpha-fetoprotein levels in peripheral blood, as measured in the clinical laboratory.
David Steffin retweeted
A 3-year-old boy with chemotherapy-resistant metastatic hepatoblastoma had complete regression lasting at least 12 months after two infusions of glypican-3–specific CAR T cells coexpressing interleukin-15 and interleukin-21. Read the full correspondence: nej.md/46a2Iut
ALT The image is a graph showing alpha-fetoprotein levels in peripheral blood, as measured in the clinical laboratory.
David Steffin retweeted
Excited to share our work in @NEJM! A child with refractory hepatoblastoma achieved a durable complete response after IL-15/IL-21 GPC3 CAR T cells.
Grateful to the patient & family and @AndrasHeczey, @CAGT, @BCM, @TexasChildrens, @SeattleChildrens & @NIH!
nejm.org/doi/10.1056/NEJMc26…
Excited to share our work in @NEJM! A child with refractory hepatoblastoma achieved a durable complete response after IL-15/IL-21 GPC3 CAR T cells.
Grateful to the patient & family and @AndrasHeczey, @CAGT, @BCM, @TexasChildrens, @SeattleChildrens & @NIH!
nejm.org/doi/10.1056/NEJMc26…
David Steffin retweeted
🎯 GPC3 is emerging as a compelling CAR-T target in solid tumors, but optimization is key. David Steffin (@davidsteffin) presents strategies for improving GPC3 CAR T cells in relapsed/refractory disease at #iwCART26
#CART
Was a pleasure to present and participate at the CanACT annual steering committee! Such a great opportunity to hear about the amazing research investments being made in solid tumor cell therapy trials. @NCIDirector @theNCI @bcmhouston
I had a great discussion yesterday with the Can-ACT Annual Steering Committee. These conversations are essential to advancing cell-based therapies, and they reflect @theNCI’s commitment to supporting the collaborations needed to translate promising science into better outcomes.
David Steffin retweeted
I had a great discussion yesterday with the Can-ACT Annual Steering Committee. These conversations are essential to advancing cell-based therapies, and they reflect @theNCI’s commitment to supporting the collaborations needed to translate promising science into better outcomes.
David Steffin retweeted
After presenting at #CellCoast, David Steffin, MD (@davidsteffin) of @TexasChildrens shares promising results from a GPC3 CAR T cell trial for solid tumors, and details a new trial in adults and children building on this work.
Great opportunity to present our work on GPC3 CAR T cells for children and adults with treatment refractory solid tumors at #cellcoast25 @MoffittNews @TexasChildrens @bcmhouston thank you to the sponsors for hosting!
Happening now at #CellCoast25 David Steffin, MD (@davidsteffin) of @TexasChildrens discusses GPC3 CAR T cells for patients with solid tumors.
Key Takeaways:
➡️ GPC3 is a safe and promising target for treating multiple solid tumors.
➡️ IL15 enhances the expansion and antitumor activity of GPC3 CAR T cells, while IL1/6 inhibition or iC9 can help manage CRS.
➡️ Tumor-infiltrating CAR T cells show NK-like differentiation, stronger proliferation, and activation of Type I IFN and FOS/JUN pathways linked to response.
➡️ Early findings suggest IL15/IL21 dual expression could further boost antitumor efficacy safely
David Steffin retweeted
🎉 Thank you all for CAR T day 2025!
What an exceptional gathering of minds, ideas, and innovation in the field of CAR T-cell therapy! 💡🧬
🙏 A heartfelt thank you to all participants, speakers, exhibitors, and partners who made this event a true success. Your presence and engagement helped shape a memorable edition! 🌍✨
📌 Some key figures from this year’s event:
😊 Over 160 participants
📚 12 scientific sessions
🥗 1 lunch symposium
🎤 44 speakers
📄 14 posters and 4 oral presentations
🤝 5 sponsors, including 3 exhibitors
🎉 Social highlight: a gala dinner on the beautiful boat KOK PIRAAT, on Thursday evening, September 11th
🚨 Save the date for the next edition... September 10 & 11 2026!
#CARTday #CARTday2025 #CARcells #Lille2025 #InternationalEvent #eventprofs
@CHU_Lille - @univ_lille - @sfiimmunologie - @i_yakoub_agha - @aljurf100 - @H_Einsele - @LaurieMengerLab - @RoychoudhuriLab - @DrOlivierBoyer
Very promising news and an honor to be a part of this report! @CAGTHouston @BCMFromtheLabs @TexasChildrens
nature.com/articles/s41591-0…
David Steffin retweeted
#CARTcells armed with #IL15 show promise in treating solid #cancers cancerletter.com/clinical-ro… @HeczeyAndras ZP Sumazin, C Rooney, M Brenner, @davidsteffin @bcmhouston @TexasChildrens @CAGTHouston @Nature
David Steffin retweeted
How #scientists make #breakthroughs: a journey to finding a promising method to address #CARTcell challenges in treating #solidTumors. @HeczeyAndras ZP Sumazin, C Rooney, M Brenner @davidsteffin @bcmhouston @TexasChildrens @CAGTHouston @Nature blogs.bcm.edu/2025/01/28/fro…
Promising results from our phase 1 trials using GPC3-CAR T cells co-expressing IL-15 in relapsed/refractory solid tumors. @HeczeyAndras @HeczeyLab @Nature @BCMFromtheLabs @BCMCancerCenter @CAGTHouston
nature.com/articles/s41586-0…
David Steffin retweeted
IL15 increases the expansion of CAR T cells and induces antitumor responses in patients with GPC3+ solid tumors (i.e. liver cancer).
nature.com/articles/s41586-0…
Had the honor of moderating a great session today at ASGCT! Gt at way to end the meeting!! #ASGCT2023
David Steffin retweeted
Read about CAR-NKT cell therapy shows promising results against neuroblastoma in phase 1 clinical trial here: bcm.edu/news/car-nkt-cell-th…
David Steffin retweeted
GD2-CAR.15 NKTs are safe and can mediate objective responses in patients with NB. Additionally, their anti-tumor activity may be enhanced by targeting BTG1.
@BCMCancerCenter @TexasChildrens
nature.com/articles/s41591-0…
David Steffin retweeted
Emerging results from 24 patients treated with GPC3-CAR or IL15.GPC3-CAR T cells with solid tumors presented by @davidsteffin #ASGCT23 #Immunotherapy @BCMCancerCenter @TCHResearchNews @CAGTHouston
